Andere Sprachen Atai Life Sciences N.V.

Aktien

A3CSB4

NL0015000DX5

ATAI

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:36:10 01.05.2024			% 5 Tage	% 1. Jan.
2 ^USD	+1.01%		+4.81%	+39.01%

24.04.	Atai Life Sciences gibt die Verabreichung des ersten Patienten in Teil 2 der Phase-2a-Studie von Beckley Psytech zur Erforschung von BPL-003 als Zusatztherapie zu SSRIs bei Patienten mit behandlungsresistenten Depressionen bekannt	CI
17.04.	Atai Life Sciences gibt die Veröffentlichung der Phase-1-Studie von Beckley Psytech zu BPL-003 im Journal of Psychopharmacology bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	25.04.
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24.04.
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24.04.
Clarify Pharma to change name to File Forge Technology	17.04.
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17.04.
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17.04.
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements	08.04.
Sector Update: Health Care Stocks Softer Late Afternoon	03.04.
Atai Life Sciences Shares Rise Following Maxim Upgrade	03.04.
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 in Treatment Resistant Depression	28.03.
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28.03.
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28.03.
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27.03.
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27.03.
Atai Life Sciences advances VLS-01 for treatment-resistant depression	12.03.
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11.03.
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11.03.
Atai Life Sciences N : Company Presentation March 2024	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Atai Life Sciences N.V.

Aktien

A3CSB4

NL0015000DX5

ATAI

Andere Sprachen

Filter